Open AccessHematologic aspects of myeloablative therapy and bone marrow transplantation
Author(s) -
Riley Roger S.,
Idowu Michael,
Chesney Alden,
Zhao Shawn,
McCarty John,
Lamb Lawrence S.,
BenEzra Jonathan M.
Publication year - 2005
Publication title -
journal of clinical laboratory analysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.536
H-Index - 50
eISSN - 1098-2825
pISSN - 0887-8013
DOI - 10.1002/jcla.20055
Subject(s) - medicine , bone marrow , haematopoiesis , myelofibrosis , stem cell , transplantation , leukemia , pathology , immunology , biology , genetics
The transplantation of bone marrow cells or isolated hematopoietic stem cells from the bone marrow or peripheral blood is a widely utilized form of therapy for patients with incurable diseases of the hematopoietic and immune systems. Successful engraftment of the transplanted stem cells in an adequately prepared recipient normally leads to bone marrow reconstitution over a period of several weeks, accompanied by more gradual reconstitution of the immune system. Since the recipient is profoundly ill during the initial treatment period, laboratory data is critical for monitoring engraftment, detecting residual/recurrent disease, and identifying problems that may delay bone marrow reconstitution or lead to other medical complications. Accurate blood cell counts are imperative, and most bone marrow transplantation patients undergo periodic monitoring with bone marrow aspirates and biopsies with cytogenetic, molecular, and multiparametric flow cytometric studies. The potential complications of bone marrow transplantation include engraftment failure and delayed engraftment, infection, residual bone marrow disease, acute and chronic graft versus host disease, myelofibrosis, therapy‐related acute leukemia, post‐transplant lympho‐proliferative disorders, and toxic myelopathy. J. Clin. Lab. Anal. 19:47–79, 2005. © 2005 Wiley‐Liss, Inc.